Detection and prevention of common interference in turbidimetric immunoassay

doi:10.3969/j.issn.1673-8640.2021.04.002

Abstract

Abstract:

The accuracy of turbidimetric immunoassay is affected by a few interference factors,such as sample appearance,endogenous interference,hook effect and carry-over contamination. These interference factors may cause the results increasing or decreasing falsely and further affect clinical diagnosis and treatment monitoring. The laboratory staff should be familiar with common interference factors and mechanisms,communicate with doctors in time and identify,confirm and prevent possible interference,in order to reduce the occurrence of adverse events.

Key words: Turbidimetric immunoassay, Sample appearance, Endogenous interference, Hook effect, Carry-over contamination, Interference

CLC Number:

R446.1

JIA Keke, SUN Wenyuan, NIE Rui, CUI Liyan. Detection and prevention of common interference in turbidimetric immunoassay[J]. Laboratory Medicine, 2021, 36(4): 362-368.

Figures/Tables 1

References 44

[1]	Clinical and Laboratory Standards Institute. Hemolysis,icterus,and lipemia/turbidity indices as indications of interference in clinical laboratory analysis[S]. C56-A,CLSI, 2012.
[2]	彭凤, 徐晓萍, 王琳, 等. 免疫透射比浊法和免疫散射比浊法检测特定蛋白的抗干扰能力比较[J]. 检验医学, 2013,28(2):142-145. DOI URL
[3]	夏良裕, 徐二木, 曹新策, 等. 溶血对41个生化免疫项目的影响评估及溶血警告指数的确立[J]. 中华检验医学杂志, 2017,40(12):947-952.
[4]	HEIREMAN L, VAN GEEL P, MUSGER L, et al. Causes,consequences and management of sample hemolysis in the clinical laboratory[J]. Clin Biochem, 2017,50(18):1317-1322. DOI URL PMID
[5]	刘蕊, 李刚, 崔小璠. 胆红素和血红蛋白对不同尿白蛋白检测方法结果干扰的研究[J]. 检验医学, 2012,27(7):564-567.
[6]	郭洪晨, 刘静. 胆红素对临床检验结果的干扰及消除[J]. 检验医学与临床, 2009,6(18):1573-1575.
[7]	国秀芝, 邱玲, 刘荔, 等. 三种应用于自动生化分析仪的半胱氨酸蛋白酶抑制剂C试剂的分析性能验证[J]. 中华检验医学杂志, 2011,34(6):561-567.
[8]	陈华, 王永卿. 免疫透射比浊法测定类风湿因子的应用评价[J]. 国际检验医学杂志, 2008,29(1):21-22.
[9]	周云祥, 闻平, 吴志勇. 免疫透射比浊法测定血清前白蛋白方法学探讨[J]. 现代检验医学杂志, 2004,19(6):11-12.
[10]	SIMONSON P D, KIM K H, WINSTON-MCPHERSON G, et al. Characterization of bilirubin interference in three commonly used digoxin assays[J]. Clin Biochem, 2019,63:102-105. DOI URL PMID
[11]	VON MEYER A, CADAMURO J, LIPPI G, et al. Call for more transparency in manufacturers declarations on serum indices:on behalf of the Working Group for Preanalytical Phase(WG-PRE),European Federation of Clinical Chemistry and Laboratory Medicine(EFLM)[J]. Clin Chim Acta, 2018,484:328-332. DOI URL PMID
[12]	WAN AZMAN W N, OMAR J, KOON T S, et al. Hemolyzed specimens:major challenge for identifying and rejecting specimens in clinical laboratories[J]. Oman Med J, 2019,34(2):94-98. DOI URL PMID
[13]	CADAMURO J, MRAZEK C, HASCHKE-BECHER E, et al. To report or not to report:a proposal on how to deal with altered test results in hemolytic samples[J]. Clin Chem Lab Med, 2017,55(8):1109-1111. DOI URL PMID
[14]	梁紫薇. 乳糜血影响生化项目检测结果的研究进展[J]. 检验医学与临床, 2018,15(10):1531-1533.
[15]	HUNSAKER J J H, LA'ULU S L, WYNESS S P, et al. Lipemic interference of ceruloplasmin assays-an evaluation of lipid removal methods[J]. Clin Chim Acta, 2018,480:71-78. DOI URL PMID
[16]	HUNSAKER J J H, WYNESS S P, NEEDHAM L L, et al. Evaluation of L-index interference limits on Roche cobas c502 and c702 immunoturbidimetric assays using endogenously lipemic specimens and intralipid spiking[J]. Clin Biochem, 2019,70:18-23. DOI URL PMID
[17]	MONGOLU S, ARMSTON A E, MOZLEY E, et al. Heterophilic antibody interference affecting multiple hormone assays:is it due to rheumatoid factor?[J]. Scand J Clin Lab Invest, 2016,76(3):240-242. DOI URL PMID
[18]	MOORE T L, DORNER R W. Rheumatoid factors[J]. Clin Biochem, 1993,26(2):75-84. DOI URL PMID
[19]	TASLIYURT T, KISACIK B, KAYA S U, et al. The frequency of antibodies against cyclic citrullinated peptides and rheumatoid factor in healthy population:a field study of rheumatoid arthritis from northern Turkey[J]. Rheumatol Int, 2013,33(4):939-942. DOI URL
[20]	KENNY P R, FINGER D R. Falsely elevated cardiac troponin-I in patients with seropositive rheumatoid arthritis[J]. J Rheumatol, 2005,32(7):1258-1261. URL PMID
[21]	TSAVARIS N, MAVRAGANI C P, PIKAZIS D. Rheumatoid arthritis:correlation between rheumatoid factor levels and CA-125 tumour marker elevation[J]. Ann Rheum Dis, 2007,66(7):980. DOI URL PMID
[22]	XU L, YU Z, FAN W, et al. Negative interference in serum HBsAg ELISA from rheumatoid factors[J]. PLoS One, 2013,8(11):e80620. DOI URL PMID
[23]	BARCELÓ MARTÍN B, MARQUET P, FERRER J M, et al. Rheumatoid factor interference in a tacrolimus immunoassay[J]. Ther Drug Monit, 2009,31(6):743-745. DOI URL PMID
[24]	OHTAKE T, KANO S, WATANABE K. Interference in turbidimetric immunoassay for serum C-reactive protein due to serum protein abnormalities an immune complex and rheumatoid factor[J]. Rinsho Byori, 2000,48(8):752-759. URL PMID
[25]	KITAAKI S, HAYASHI N, SATO I, et al. Factors affecting non-specific reaction in latex agglutination turbidimetric immunoassay for detection of matrix metalloproteinase-3[J]. Rinsho Byori, 2015 , 63(4):427-434. URL PMID
[26]	黄佳芝, 徐萍, 刘宇嘉. 类风湿因子干扰免疫比浊法测定胱抑素C的原因(1例)[J]. 医疗装备, 2017,30(17):58-59.
[27]	BOLSTAD N, WARREN D J, NUSTAD K. Heterophilic antibody interference in immunometric assays[J]. Best Pract Res Clin Endocrinol Metab, 2013,27(5):647-661. DOI URL PMID
[28]	LIPPI G, ALOE R, MESCHI T, et al. Interference from heterophilic antibodies in troponin testing. Case report and systematic review of the literature[J]. Clin Chim Acta, 2013,426:79-84. DOI URL
[29]	ROUVIÈRE J A, DEVIGNES J, DE MAISTRE E, et al. Discrepancy between two methods of D-dimers measurement:one case of human anti-mouse antibody interference[J]. Ann Biol Clin(Paris), 2008,66(4):441-446.
[30]	DIMESKI G, CARTER A. Rare IgM interference with Roche/Hitachi modular glucose and gamma-glutarnyltransferase methods in heparin samples[J]. Clin Chem, 2005,51(11):2202-2204. DOI URL PMID
[31]	李江, 王立伟, 赵兴波, 等. 罕见的IgA型M蛋白对临床化学检测的干扰及分析[J]. 标记免疫分析与临床, 2011,18(6):398-402.
[32]	SMOGORZEWSKA A, FLOOD J G, LONG W H, et al. Paraprotein interference in automated chemistry analyzers[J]. Clin Chem, 2004,50(9):1691-1693. DOI URL PMID
[33]	沈敏娜, 吴炯, 郭玮, 等. M蛋白干扰对血清样本常规生化检测项目的影响[J]. 检验医学, 2011,26(11):730-735.
[34]	WU X Y, YIN Y F, TENG J L, et al. IgMκ paraprotein from gammopathy patient can bind to cardiolipin and interfere with coagulation assay:a case report[J]. BMC Immunol, 2017,18(1):32. DOI URL PMID
[35]	HIRATA K, SARUWATARI J, ENOKI Y, et al. Possible false-negative results on therapeutic drug monitoring of phenytoin using a particle enhanced turbidimetric inhibition immunoassay in a patient with a high level of IgM[J]. Ther Drug Monit, 2014,36(5):553-555. DOI URL PMID
[36]	KING R I, FLORKOWSKI C M. How paraproteins can affect laboratory assays:spurious results and biological effects[J]. Pathology, 2010,42(5):397-401.
[37]	韩建华, 程歆琦, 吴洁, 等. M蛋白对免疫透射比浊法和免疫散射比浊法检测免疫球蛋白的干扰[J]. 检验医学, 2019,34(3):197-201.
[38]	ISMAIL A A. Identifying and reducing potentially wrong immunoassay results even when plausible and “not-unreasonable”[J]. Adv Clin Chem, 2014,66:241-294.
[39]	BARTELS E M, FALBE W I, LITTRUP A E, et al. Rheumatoid factor and its interference with cytokine measurements:problems and solutions[J]. Arthritis, 2011,2011:741071. URL PMID
[40]	杨杰, 李茂城, 尹小毛, 等. 27项特定蛋白项目检测结果分析及钩状效应的防范方法[J]. 检验医学与临床, 2019,16(1):8-12.
[41]	张杰良, 黄雪珍, 莫和国, 等. 尿微量清蛋白抗原再添加检测技术与前带检查研究分析[J]. 重庆医学, 2017,46(28):3962-3964.
[42]	杨杰, 李玲, 张瀚允, 等. 5种免疫透射比浊法试剂盒检测特定蛋白钩状效应的性能评估[J]. 国际检验医学杂志, 2019,40(2):140-143.
[43]	ZAYDMAN M A, BRESTOFF J R, LOGSDON N, et al. Kinetic approach extends the analytical measurement range and corrects antigen excess in homogeneous turbidimetric immunoassays[J]. J Appl Lab Med, 2019,4(2):214-223. URL PMID
[44]	夏勇, 薛灏, 李明洋, 等. 免疫透射比浊法自建检测系统钩状效应性能确认方法的建立[J]. 检验医学, 2018,33(12):1132-1135.

检测系统	载脂蛋白A1	载脂蛋白B	脂蛋白（a）	ASO^④	RF	β₂-微球蛋白	补体C3	补体C4
AU5800
LI[脂肪乳剂/（mg/L）]^①	50	20.0~29.9		50	50	50	50	50
II[胆红素/（mg/L）]^②	4	4		4	4	4	4	4
HI[Hb/（mg/L）]^③	50	50		50	50	50	50	50
cobas c701/c702
LI（Intralipid脂肪乳剂）^④	100	100	200	100	200	75	100	100
II[结合胆红素/（mg/L）]^⑤	6	6	6	2.6	4/6	5.4	6	6
HI[Hb/（mg/L）]^⑥	100	100	100	100	30	100	100	100

检测系统	载脂蛋白A1	载脂蛋白B	脂蛋白（a）	ASO^④	RF	β₂-微球蛋白	补体C3	补体C4
AU5800
LI[脂肪乳剂/（mg/L）]^①	50	20.0~29.9		50	50	50	50	50
II[胆红素/（mg/L）]^②	4	4		4	4	4	4	4
HI[Hb/（mg/L）]^③	50	50		50	50	50	50	50
cobas c701/c702
LI（Intralipid脂肪乳剂）^④	100	100	200	100	200	75	100	100
II[结合胆红素/（mg/L）]^⑤	6	6	6	2.6	4/6	5.4	6	6
HI[Hb/（mg/L）]^⑥	100	100	100	100	30	100	100	100